文章摘要
温少迪,沈 波.非小细胞肺癌免疫治疗作用机制及临床研究现状[J].南京医科大学学报,2020,(11):1739~1746
非小细胞肺癌免疫治疗作用机制及临床研究现状
Mechanisms and clinical research status of immunotherapy for non⁃small cell lung cancer
投稿时间:2020-04-12  
DOI:10.7655/NYDXBNS20201130
中文关键词: 非小细胞肺癌  免疫检查点抑制剂  肺癌联合治疗  新辅助免疫治疗  晚期NSCLC免疫治疗
英文关键词: non⁃small cell lung cancer  immune checkpoint inhibitor  lung cancer combined therapy  neoadjuvant immunotherapy  advanced NSCLC immunotherapy
基金项目:国家自然科学基金(81972822);连云港市蕙兰公益基金会(HL?HS2020?102)
作者单位
温少迪 南京医科大学附属肿瘤医院肿瘤内科江苏 南京 210009 
沈 波 南京医科大学附属肿瘤医院肿瘤内科江苏 南京 210009 
摘要点击次数: 839
全文下载次数: 331
中文摘要:
      肺癌是全球发病率与病死率较高的恶性肿瘤之一,肺癌分为小细胞肺癌(small cell lung cancer,SCLC)和非小细胞肺癌(non?small cell lung cancer,NSCLC),其中NSCLC约占肺癌的85%。NSCLC的传统治疗方法主要是外科手术、化学治疗、放射治疗以及靶向治疗,免疫检查点抑制剂的出现使肺癌的治疗进入免疫治疗时代。文章围绕免疫治疗的作用机制、免疫检查点新进展、晚期NSCLC的免疫治疗、局部晚期NSCLC的免疫治疗最新研究进展进行阐述。
英文摘要:
      Lung cancer is one of the malignant tumors with high morbidity and mortality in the world. Lung cancer is divided into small cell lung cancer (SCLC) and non?small cell lung cancer (NSCLC),of which NSCLC accounts for about 85% of lung cancer. The traditional treatment of NSCLC mainly is surgery,chemotherapy,radiotherapy and targeted therapy. The emergence of immune checkpoint inhibitors takes the treatment of lung cancer into the era of immunotherapy. This article focused on the mechanism of immunotherapy,the new progress of immune checkpoints,the immunotherapy of advanced NSCLC and the latest research progress of immunotherapy in locally advanced NSCLC.
查看全文   查看/发表评论  下载PDF阅读器